Abbott announced an agreement with Spain-based global biotech leader mAbxience Holdings to commercialize several biosimilars focusing on oncology, women’s health and respiratory diseases in emerging markets. The first molecules are expected to launch in 2025, while others are subject to the completion of clinical development and registration. Abbott will register and commercialize the biosimilars in key emerging countries in Latin America, Southeast Asia, the Middle East and Africa, leveraging the company’s broad in-country footprint to make these cutting-edge medicines available to more people in emerging countries. mAbxience, with majority ownership from Fresenius Kabi and partial ownership from Insud Pharma, will manufacture the biosimilars in one of its two state-of-the art and Good Manufacturing Practices-approved facilities in Spain and Argentina. Additionally, mAbxience will be responsible for achieving the clinical milestones for some of the molecules still undergoing development. This collaboration will commercialize biosimilars in select key emerging markets.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ABT:
- Abbott’s TactiFlex Ablation Catheter used to treat AFib in Alberta
- Abbott tells The Fly physicians can continue to use Proclaim, Infinity systems
- FDA identifies Abbott Proclaim recall as Class I
- Abbott to Acquire Bigfoot Biomedical, Furthering Efforts to Develop Personalized, Connected Solutions for People with Diabetes
- Abbott to acquire Bigfoot for undisclosed amount